Methicillin resistant stahphylococcus aureus (MRSA) septicemia in pemphigus foliaceus - A coalition partners in resistant cases
DOI:
https://doi.org/10.66344/jpad.v29i4.1340Keywords:
MRSA, pemphigus foliaceusAbstract
Infection contributes to considerable morbidity and mortality in patients with autoimmune bullous disorders (AIBDs) such as pemphigus. Increased susceptibility to infection in this population may occur via 3 primary mechanisms- defective barrier function as a result of blistering and subsequent erosions, down regulation of immunity due to medications used in the treatment of AIBDs and finally, immune dysregulation associated with autoimmunity. In pemphigus, sepsis is the most common cause of death, with staphylococcus aureus being the most frequently implicated organism. We hereby report two cases of methicillin resistant staphylococcus aureus (MRSA) septicemia in pemphigus foliaceus (PF) patients rendering them resistant to conventional immunosuppressive therapies.
References
1. Lehman JS, Murrell DF, Camilleri MJ, Kalaaji AN. Infection and Infection Prevention in Patients Treated with Immunosuppressive Medications for Autoimmune Bullous Disorders. Dermatol Clin. 2011; 29: 5 91-8.
2. A.R. Ahmed, R. Moy. Death in pemphigus. J Am Acad Dermatol. 1982; 7: 221–228.
3. Hammers CM, Stanley JR. Desmoglein-1, differentiation, and disease. J Clin Invest. 2013; 123: 1419-22.
4. Whittock NV, Bower C. Targetting of desmoglein 1 in inherited and acquired skin diseases. Clin Exp Dermatol.2003;28:410-5
5. Amagai M. Desmoglein as a target in autoimmunity and infection. J Am Acad Dermatol.2003; 48: 244-52.
6. Hanakawa Y, Stanley JR. Mechanisms of blister formation by staphylococcal toxins. J Biochem 2004; 136: 747-50.
Downloads
Published
Issue
Section
License
Copyright (c) 2019 Anuradha Jindal, Raghavendra Rao
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
